See more : Cultural Investment Holdings Co.,Ltd (600715.SS) Income Statement Analysis – Financial Results
Complete financial analysis of IMARA Inc. (IMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMARA Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Stream Media Corporation (STEAF) Income Statement Analysis – Financial Results
- Kadem Sustainable Impact Corporation (KSICW) Income Statement Analysis – Financial Results
- Katoro Gold plc (KAT.L) Income Statement Analysis – Financial Results
- Latitude Group Holdings Limited (LFS.AX) Income Statement Analysis – Financial Results
- InfoBeans Technologies Limited (INFOBEAN.BO) Income Statement Analysis – Financial Results
IMARA Inc. (IMRA)
About IMARA Inc.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.94M | 38.44M | 32.15M | 19.01M | 8.24M |
| General & Administrative | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Other Expenses | -97.00K | -175.00K | -145.00K | 75.00K | 0.00 |
| Operating Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Cost & Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Interest Income | 943.00K | 233.00K | 483.00K | 578.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -69.39M | 99.00K | 97.00K | 33.00K | -660.00K |
| EBITDA | -68.66M | -51.34M | -41.60M | -24.08M | -11.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 730.00K | -51.44M | -41.70M | -24.12M | -10.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 846.00K | 58.00K | 338.00K | 653.00K | -660.00K |
| Income Before Tax | 1.58M | -51.38M | -41.36M | -23.46M | -11.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 88.00K | -233.00K | -483.00K | -578.00K | 0.00 |
| Net Income | 1.58M | -51.15M | -40.88M | -22.89M | -11.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| EPS Diluted | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| Weighted Avg Shares Out | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
| Weighted Avg Shares Out (Dil) | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
Imara to Webcast Conference Call of Third Quarter Financial Results
Thalassemia Treatment Market Size, 2020 Growth, Types, Trends, Size, Share and Top Key Players by Forecast Research 2025
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
Wall Street Breakfast: The Week Ahead
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
Source: https://incomestatements.info
Category: Stock Reports